No Detail Found!

Effect of vascular endothelial growth factor sirna-loaded nanoparticles with doxorubicin in inhibiting the growth of breast cancer in xenograft mouse model

Author(s)
X. H. Li The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
S. Y. Sun The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
X. C. Yue The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
S. Zhang The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
L.Y. Qian The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
J. Tang The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
F. Q. Jiang The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
J. F. Lu The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
Y. F. Cao The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
S. W. Meng The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
T. J. Yao The First Affiliated Hospital of Bengbu Medical College,Bengbu , Anhui,China
Abstract
As an antineoplastic antibiotic, doxorubicin (DOX) effectively inhibits RNA and DNA synthesis. However, its application is limited by side effects and drug resistance. This study established a xenograft mouse model of breast cancer (BC) to investigate the therapeutic efficacy of a gene/drug nano-delivery system combining vascular endothelial growth factor (VEGF) silencing with DOX for treating BC. Poly (lactic acid) (PLA) was utilized as the carrier material to prepare nanoparticles (NPs) loaded with VEGF interference RNA (siRNA) and the chemotherapeutic drug DOX (PLA/DOX-NPs and PLA/DOX-siVEGF-NPs). The characterization and drug release of NPs were analyzed. NPs' cytotoxicity was determined by CCK-8 assay with HUVEC and MCF-7 cells. The BC xenograft (BCX) model was established by injecting MCF-7 cells into the mammary fat pads of nude mice. The differences in tumor weight and tumor inhibition rate were analyzed after treatment with DOX alone, PLA/DOX-NPs, and PLA/DOX-siVEGF-NPs. Immunohistochemical staining was employed to examine Ki-67 positive expression rate in the BCXs. Western blot was used to detect Ki-67 and VEGF protein expression levels in transplanted tumor tissues. Additionally, a suspension of BCX cells was injected subcutaneously into healthy nude mice to assess tumor growth after secondary engraftment. Both PLA/DOX-NPs and PLA/DOX-siVEGF-NPs demonstrated sustained release of DOX in buffer media at varying pH values, with no visible difference in inhibiting human umbilical vein endothelial cells (HUVECs) proliferation. After establishment of the BCX mouse model, compared to DOX group, the PLA/DOX-NPs group and PLA/DOX-siVEGF-NPs group exhibited a significant reduction in relative tumor volume and Ki-67 index, along with an increased tumor inhibition rate. Furthermore, after secondary tumor formation, both tumor volume and size were markedly reduced (P<0.05). There were statistically significant differences in various parameters between the PLA/DOX-NPs group and the PLA/DOX-siVEGF-NPs group (P<0.05). The prepared PLA/DOX-siVEGF-NPs demonstrated low toxicity to normal cells and strongly inhibited the proliferation of MCF-7 BC cells in vitro. Moreover, PLA/DOX-siVEGF-NPs effectively inhibited the growth of BCXs in nude mice and suppressed Ki-67 positive expression. This treatment also reduced the malignant differentiation of the tumors and inhibited tumor recurrence.
Publication Details
Page(s) 612-624
Published Journal: Journal of Animal and Plant sciences, Volume: 35, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
xenograft mouse model, Breast cancer, Vascular endothelial growth factor, Nanoparticles, Doxorubicin
References
Aydin O.,Kanarya D.,Yilmaz U.,Ü C.,Tunç C. .2022 .Determination of optimum ratio of cationic polymers and small interfering RNA with agarose gel retardation assay. Methods Mol. Biol, 2434 : 7-128.
Ahmadpour S.T.,Desquiret-Dumas V.,Yikilmaz U.,Dartier J.,Wetterwald C.,Orre C.,Gueguen N.,Brisson L.,Mahéo K.,Dumas J.F. .2021 .Doxorubicin-induced autophagolysosome formation is partly prevented by mitochondrial ROS elimination in DOX-resistant breast cancer cells. Int. J. Mol. Sci, 9283(17) : .
Barenholz Y. .2012 .--the first FDA-approved nano-drug: lessons learned. J. Control Release, 160(2) : 117-134.
.2012 .. , 03 : .
Banerjee K.,Kerzel T.,Bekkhus T.,Wallmann T.,Wallerius M.,Landwehr L.S.,Agardy D.A.,Schauer N.,Malmerfeldt A.,Bergh J.,Bartish M.,Hartman J.,Östman A.,Squadrito M.L.,Rolny C. .2023 .VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. Cell Rep, 42(12) : 113507.
.2023 .. , 113507 : .
Cao Z.,Li Y.,Luo X.,Hua Z.,Wang X.,Xue Z.,Zhang Z.,Lu C.,Lu A.,Liu Y. .2023 .MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer. Breast Cancer Res., 25(1) : .
Charbe N.B.,Amnerkar N.D.,Ramesh B.,M.M. Tambuwala H.A.,Bakshi A.A.A.,Aljabali S.C.,Khadse R.,Satheeshkumar S.,Satija M.,Metha D.K.,Chellappan P.,Negi K.,Dua F.C,Zacconi F.C .2020 .Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta. Pharm. Sin. B., 10(11) : 2075-2109.
Dekkers J.F.,Whittle J.R.,Vaillant F.,Chen H.R.,Dawson C.,Geurts M.H.,Herold M.J.,Clevers H.,Lindeman G.J.,Visvader J.E. .2020 .Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids. J. Natl. Cancer Inst., 112(5) : 540-544.
. .. , : .
Guo Q.F.,Sun J.Q. .2022 .Therapeutic effect of anti-miRNA mediated by RNA nanoparticles targeting CD133 on triple-negative breast cancer. Sci. Adv, 4269(4) : 803-809.
Hamanishi J.,Takeshima N.,Katsumata N.,Ushijima K.,Kimura T.,Takeuchi S.,Matsumoto K.,Ito K.,Mandai M.,Nakai H.,Sakuragi N.,Watari H.,Takahashi N.,Kato H.,Hasegawa K.,Yonemori K.,Mizuno M.,Takehara K.,Niikura H.,Sawasaki T.,Nakao S.,Saito T.,Enomoto T.,Nagase S.,Suzuki N.,Matsumoto T.,Kondo E.,Sonoda K.,Aihara S.,Aoki Y.,Okamoto A.,Takano H.,Kobayashi H.,Kato H.,Terai Y.,Takazawa A.,Takahashi Y.,Namba Y.,Aoki D.,Fujiwara K.,Sugiyama T.,I. Konishi T. .2021 .Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol., 39(33) : 3671-3681.
Harahap W.A.,Tofrizal T.,Oktahermoniza O. .2022 .Relationship between the expression of BRAF V600E and Ki-67 with the recurrence of well-differentiated thyroid cancer. Asian Pac. J. Cancer Prev, 23(11) : 3617-3622.
Iwamoto T.,Kajiwara Y.,Zhu Y.,Iha S. .2020 .Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. Chin Clin Oncol, 01(3) : .
Jin M.,Hou Y.,Quan X.,Chen L.,Gao Z.,Huang W. .2021 .Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties (II): co-delivery of Paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice. Int. J. Nanomedicine, 16 : 5479-5494.
Jin M.,Zeng B.,Liu Y.,Jin L.,Hou Y.,Wu H.,Chen L.,Gao Z.,W. Huang. Z. .2022 .Co-delivery of repurposing Itraconazole and VEGF siRNA by composite nanoparticulate system for collaborative anti-angiogenesis and anti-tumor efficacy against breast cancer. Pharmaceutics, 14(7) : .
Jamialahmadi K.,Zahedipour F.,G. Karimi. F. .2021 .The role of microRNAs on doxorubicin drug resistance in breast cancer. J Pharm Pharmacol, 73(8) : 997-1006.
Kopeckova K.,Eckschlager T.,Sirc J.,Hobzova R.,Plch J.,Hrabeta J.,J. Michalek. J. .2019 .Nanodrugs used in cancer therapy. Biomed. Pap. Med, 010(2) : 122-131.
Korpela H.,Hätinen O.P.,Nieminen T.,Mallick R.,Toivanen P.,Airaksinen J.,Valli K.,Hakulinen M.,Poutiainen P.,Nurro J.,Ylä-Herttuala S. .2021 .Adenoviral VEGF-B186R127S gene transfer induces angiogenesis and improves perfusion in ischemic heart. , 24(12) : 103533.
.2021 .. , 103533 : .
Karaosmanoglu S.,Zhou M.,Shi B.,Zhang X.,Williams G.R.,X. Chen. G.R. .2020 .Carrier-free nanodrugs for safe and effective cancer treatment. J. Control Release, 10 : 805-832.
Li C.,Wang H.,Fang H.,He C.,Pei Y.,Gai X. .2021 .FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway. Exp. Ther. Med, 22(3) : .
Lin Y.W.,Huang S.T.,Wu J.C.,Chu T.H.,Huang S.C.,Lee C.C.,M.H. Tai. C.C. .2019 .Novel HDGF/HIF-1α/VEGF axis in oral cancer impacts disease prognosis. BMC Cancer, 19(1) : 1083.
. .. , : .
Luchini C.,Pantanowitz L.,Adsay V.,Asa S.L.,Antonini P.,Veronese N.,Nottegar A.,Cingarlini S.,Landoni L.,Brosens L.A.,Verschuur A.V.,Mattiolo P.,Pea A.,Mafficini A.,Milella M.,Niazi M.K.,Gurcan M.N.,Eccher A.,Cree I.A.,Scarpa A .2022 .Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Mod. Pathol., 35(6) : 712-720.
LoPresti M. L.,Arral N.,Chaudhary K.A.,Whitehead K.A. .2022 .The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release, 03 : 819-831.
Mercurio A.M. .2019 .VEGF/Neuropilin Signaling in Cancer Stem Cells. Int. J. Mol. Sci, 20(3) : 490.
Maryam S.S.,Ahmed R.,Alam M.U.,Hanif M.,Saleem R.,Gul R. .2021 .Role of serum VEGF-A biomarker for early diagnosis of ovarian cancer instead of CA-125. Pakistan Med, 71(9) : 688-2197.
Mainini F.,Eccles M.R. .2020 .Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules, 25(11) : 2692.
. .. , : .
Mi X.,Hu M.,Dong M.,Yang Z.,Zhan X.,Chang X.,Lu J.,Chen X. .2021 .Folic acid decorated zeolitic imidazolate framework (ZIF-8) loaded with Baicalin as a nano-drug delivery system for breast cancer therapy. Int. J. Nanomedicine, 16 : 8337-8352.
. .. , : .
Peng Y.,Wang Y.,Tang N.,Sun D.,Lan Y.,Yu Z.,Zhao X.,Feng L.,Zhang B.,Jin L.,Yu F.,Ma X.,Lv X. .2018 .Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J. Exp. Clin. Cancer Res., 37(1) : .
Repp L.,Rasoulianboroujeni M.,Lee H.J.,Kwon G.S.,PCL G.S. .2020 .-assemblies for injection. J. Control Release, 11 : 1004-1015.
Ramasamy T.,Ruttala H.B.,Munusamy S.,Chakraborty N.,Kim J.O. .2022 .Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J. Control Release, 352 : 861-878.
.2022 .. , 10 : .
Swietach P. .2019 .What is pH regulation, and why do cancer cells need it? Cancer Metastasis Rev. , 38(1-2) : 5-15.
Solechan S.,Suprihanto A.,Widyanto S.A.,Triyono J.,Fitriyana D.F.,Siregar J.P.,Cionita T. .2023 .Characterization of PLA/PCL/Nano-Hydroxyapatite (nHA) biocomposites prepared via cold isostatic pressing. Polymers (Basel), 15(3) : .
Vitale I.,Manic G.,Coussens L.M.,Kroemer G.,L. Galluzzi. G. .2019 .Macrophages and metabolism in the tumor microenvironment. Cell Metab, 06(1) : 36-50.
Wang A.,J.S. Jiang. A. .2022 .Research on mechanism of doxorubicin carried with mesoporous silica nanoparticles mesoporous silica nanoparticles in regulating the activity of liver tumor cells through regulating the activity of Hippo-Yes-Associated protein signal pathway. Sci. Adv, 4231(3) : 521-527.
Wu J. .2021 .The Enhanced Permeability and Retention (EPR) effect: the significance of the concept and methods to enhance its application. J. Pers. Med, 11(8) : .
Zhu X.,Chen L.,Huang B.,Wang Y.,Ji L.,Wu J.,Yu K.,Shao Z.,Z. Wang. Z. .2020 .The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci. Rep, 10(1) : 225.
. .. , : .
Zhang X.,Wu Z.,Peng Y.,Li D.,Jiang Y.,Pan F.,Li Y.,Lai Y.,Cui Z.,K. Zhang. Z. .2021 .Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients. Biomed. Res. Int., 6651397 : .
0

Citations

0

Downloads

16

Views